Celltrion Receives Recommendation for Approval to Sell Avastin Biosimilar in Europe
[Asia Economy Reporter Kwon Jaehee] Celltrion announced on the 27th that it has obtained a 'marketing authorization recommendation' from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) for 'CT-P16' (Avastin biosimilar).
The recommendation was obtained on the 24th local European time, and the approved indications include ▲non-small cell lung cancer ▲metastatic colorectal cancer ▲metastatic renal cell carcinoma ▲cervical cancer ▲epithelial ovarian cancer ▲fallopian tube cancer ▲primary peritoneal cancer ▲metastatic breast cancer, among others.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051414165763158_1778735817.jpg)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- No Cure in Sight... '105 Deaths' Spark Fears as American Also Infected
- "It's Only May, but Convenience Stores Know... Iced Americano at 24°C, Tube Ice Cream at 31°C: The Thermometer of the Summer Sales Boom"
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- [Breaking] Chung Yongjin Apologizes for Starbucks 'Tank Day' Controversy: "I Take Full Responsibility"
The company stated, "With the CHMP's marketing authorization recommendation, we expect to obtain the final marketing authorization from the European Commission (EC) in the near future."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
